changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Certain BTG products may not be available within the chosen location and indications may differ from your country's approved use.
For Medical questions regarding any BTG products, please contact email@example.com
This case was impressive because of the clear visualisation of the tumour and the embolised vessels on the post-embolisation non-contrast CBCT, in addition to the complete response of the related lesions.
After 4 weeks of follow-up, a complete response on mRECIST was demonstrated with a decrease in tumour size to 0.9 mm.
The radiopaque property of DC Bead LUMI™ allows for accurate needle placement and full lesion ablation. If the lesion cannot be seen on non-contrast CT, there is a possibility that the lesion may not be fully ablated.
BTG plc acquires Novate Medical Ltd.
BTG plc acquires Roxwood Medical
BTG and SIO expand Immuno-Oncology / Int...
OPTALYSE PE Results Presented at Society...
Health Canada approves radiopaque bead f...
Healthcare Player BTG on lookout for acq...